WOLF @ $115 at 9:50.... THE WOLF- Wolfspeed, Inc. (WOLF) NOW-> $120.04+8.27(+7.40%) As of 12:30PM EST. I'm having one of my really good lucky days.
Well Van I'm moving big money tomorrow. $30,000+ trade. The stock you know. I'm going to be ABBV Boy. Selling some country fund I didn't know I had and using some cash I raised buying 200 shares for myself and 200 for my wife. My feeling - when you're on a hot streak keep pushing it.
These guys again- WISeKey to invest $10M adapting cybersecurity tech to fend-off 'crypto jacking' ยป 16:14 WKEY Global Payments initiated with a Buy at Loop Capital 16:07 GPN
Staff Online Now Magna Administrator Users Online Now Total: 379 (members: 47, guests: 317, robots: 15) WTF! 15 mother fing robots. LEAVE THE CHICKEN PICKERS ALONE! THESE ARE REAL JOBS.
Hmmmm. That's almost as good as a Stoney "guarantee". I'll look. This one QUOT is up a solid 7%. ABBV certainly has a blowout chart, that's for sure. Good call Stoney. It's a tad bit pricey on a F/A level, but as long as nothing changes, it's a good stock. If we get a nice pull-back, it'll be a great stock. *** I am usually weary of stocks with dividends in excess of 4% though. Either something is up, or water seeks its level and you're a genius.
Van TOTAL RETURN Haven't heard that phrase in a while have you... might that be the way to go in 2022?
<< Stocks To watch >> Nano Dimension sells DragonFly IV 3D-AME System to Western Defense Force 08:45 NNDM Ooooooo. Spero Therapeutics announces lifting of FDA clinical trial hold on SPR720 08:28 SPRO Craig-Hallum bullish on iSpecimen, initiates with a Buy 08:25 ISPC As previously reported, Craig-Hallum analyst Matthew Hewitt initiated coverage of iSpecimen with a Buy rating and $20 price target. "Much the way Amazon has become the go-to platform for buyers and sellers of consumer goods," the analyst believes iSpecimen can become the go-to platform for human biospecimens. While the company was founded in 2009, it has only recently reached a critical mass of buyers and sellers, with revenue for 2021 on track to be nearly triple the 2019 level, Hewitt notes. Draganfly announces it will be featured at EDGE22 08:24 DPRO This better not be market moving! AbbVie says FDA grants Breakthrough Therapy Designation to Teliso-V 08:17 ABBV AbbVie announced that the U.S. FDA granted Breakthrough Therapy Designation to investigational telisotuzumab vedotin for the treatment of patients with advanced/metastatic epidermal growth factor receptor wild type, nonsquamous non-small cell lung cancer with high levels of c-Met overexpression whose disease has progressed on or after platinum-based therapy. The FDA's BTD program is intended to expedite the development and review of medicines with preliminary clinical evidence that indicate that the investigational treatment may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.
GUMMY/ BUY SPRO Spero Therapeutics, Inc. (SPRO) 15.15-0.86(-5.37%) At close: January 3 04:00PM EST 15.65+0.50(+3.30%)<-------- Pre-Market:08:56AM EST